Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Merck has partnered with company builder mantro GmbH to launch EdiMembre, a deep-tech spinout that will commercialize Merck's ...

Tech rout led to another session of weakness on Wall Street on Tuesday as heavily-weighted Nvidia (NVA), peer AMD (AMD), and ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...

Merck & Co., Inc. just released its 2024/2025 Impact Report, highlighting its strategic sustainability efforts. The report ...

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

Merck announced a significant regulatory milestone with a Breakthrough Therapy designation for its lung cancer drug. This FDA ...